A large group of tubulin-binding microtubule-depolymerizing agents act as tumour vascular disrupting agents (VDAs). Several members of this group are now in clinical trials in combination with conventional anticancer drugs and radiotherapy. Here we briefly update on the development of tubulin-binding combretastatins as VDAs, summarize what is known of their mechanisms of action and address issues relating to treatment resistance, using disodium combretastatin A-4 3-O-phosphate (CA-4-P) as an ...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Tumour vascular disrupting agents: combating treatment resistance.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record